News tagged with clopidogrel
Related topics: patients , heart attack , thrombosis , aspirin , blood clots
Clopidogrel is an oral, thienopyridine class antiplatelet agent used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is marketed by Bristol-Myers Squibb and Sanofi-Aventis under the trade name Plavix. The drug works by irreversibly inhibiting a receptor called P2Y12, an adenosine diphosphate ADP chemoreceptor. Adverse effects include hemorrhage, severe neutropenia, and thrombotic thrombocytopenic purpura (TTP).
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
Researchers study under-recognised and under-treated prothrombotic condition: High platelet reactivity despite treatment
Within the past decade, the variability in pharmacodynamic response and moderate antiplatelet efficacy of clopidogrel has raised major concerns, in particular because it is associated with an increased risk for ischemic events ...
Cardiology May 06, 2013 | not rated yet | 0